Is Semaglutide Safe Long Term? What the Evidence Actually Shows

What does long-term trial data tell us about semaglutide's safety?

The STEP programme (the pivotal trial series that led to Wegovy's UK licence) followed adults over 68 weeks, and the cardiovascular outcomes trial (SELECT) extended observation to more than four years in people with established heart disease. Across those studies, no new categories of serious harm emerged that were not already anticipated from the medicine's mechanism. The STEP 1 paper, published in the New England Journal of Medicine, recorded the side-effect profile in detail: gastrointestinal events dominated, were generally mild to moderate in severity, and most resolved without stopping treatment.

That does not mean the medicine is risk-free. Nausea, vomiting, constipation, loose stools, indigestion and fatigue are common, particularly in the early weeks and after each dose increase. For most people these effects are an inconvenience rather than a reason to stop. A small proportion do need to pause or discontinue. The NHS medicines page for semaglutide lists the common, uncommon and rare effects in plain language and is worth reading alongside your patient information leaflet.

NICE's appraisal of Wegovy also reviewed the safety data before recommending it, and concluded the benefit-risk balance was favourable for adults who meet the eligibility criteria. Longer observational evidence continues to accumulate as real-world prescribing grows. If you want a thorough grounding before starting, our page on whether semaglutide is safe brings together the key evidence in one place. The honest summary: the trial data is the most rigorous evidence available, and it is generally positive, but it does not replace individual clinical assessment.

Are there risks that need more careful watching over time?

A question our prescribers hear most weeks is whether semaglutide causes lasting harm to organs like the pancreas or kidneys. Here is what is known. Acute pancreatitis is a recognised but infrequent risk. In January 2026 the MHRA published a Drug Safety Update for GLP-1 medicines specifically flagging it: if you develop severe stomach pain that radiates toward the back, with or without vomiting, seek urgent medical help and mention you take semaglutide. You can read that guidance at the MHRA Drug Safety Update page.

Gallbladder problems, including gallstones, have also been reported at a higher rate than in placebo groups across GLP-1 trials. The association is thought to be at least partly linked to rapid weight loss itself rather than the medicine alone, but it is a recognised signal nonetheless. Kidney function can be affected indirectly if severe vomiting or diarrhoea causes dehydration, staying well hydrated matters, and persistent illness should prompt a call to your healthcare team.

On the other side of the ledger, the SELECT cardiovascular outcomes data showed a significant reduction in major cardiovascular events in eligible adults, a meaningful long-term benefit that goes beyond weight reduction. That is why semaglutide holds a separate UK licence for cardiovascular risk reduction, and our dedicated page on semaglutide long-term safety explores what the accumulating evidence means for people taking it over months and years. Anyone weighing up whether to commit to extended treatment will also find our page on how safe Wegovy is long term a useful place to look at the evidence in more depth. The Wegovy treatment overview covers the full licensed indications if you want the broader context.

When should you get medical help, and what counts as urgent?

Most people on semaglutide will experience manageable gastrointestinal symptoms at some point. Gritting through mild nausea is different from ignoring a warning sign. Seek prompt medical attention (the same day or via 999/A&E if severe) for any of the following: severe or persistent abdominal pain, especially if it spreads to the back; signs of a serious allergic reaction (swelling of the face, throat or tongue, difficulty breathing, rapid heartbeat); yellowing of the skin or eyes; symptoms of severe dehydration after repeated vomiting or diarrhoea (dizziness, very dark urine, inability to keep fluids down); or any significant change in mood, including thoughts of self-harm.

If you notice any side effect that concerns you, do not simply stop the medicine without speaking to your prescriber first, stopping abruptly is usually fine medically, but your clinical team can help you taper sensibly and investigate whether the symptom is related to semaglutide. You can also report any suspected side effect directly through the Yellow Card scheme, which helps the MHRA track real-world safety signals over time.

People who are thinking about stopping semaglutide for any reason (side effects or otherwise) will find it useful to understand what to expect when the medicine is discontinued. That page covers the practicalities clearly.

Who should not use semaglutide, and what conversations matter before starting?

Semaglutide is not suitable for everyone. Pregnancy, breastfeeding, and actively trying to conceive are all situations where the medicine is not recommended; effective contraception is advised while taking it, with a wash-out period before attempting conception. Under-18s are outside the licensed population. A personal or close family history of medullary thyroid carcinoma or a condition called MEN2 (multiple endocrine neoplasia type 2) is a contraindication. A history of pancreatitis, serious gastrointestinal conditions, or certain kidney or liver disease warrants careful prescriber review.

None of this is a reason to rule yourself out without asking. It is the reason the consultation process at nume exists, a GPhC-registered Independent Prescriber reviews your health history, not a checkbox algorithm. If you want to read more about the broader safety picture before that conversation, our page on whether Wegovy is safe for long-term use goes into further detail, and our clinical team is available for aftercare questions seven days a week once you are on treatment.